Please login to the form below

Not currently logged in

Astellas Pharma sees drop in Q2 income

Astellas reports a fall in income for the second quarter of 2011, as R&D and administrative expenses rise

Astellas Pharma, the Japanese pharmaceutical company, has posted a 36 per cent fall in net income to 25.1bn yen in the second quarter of 2011.

The company reported that net sales increase by 6 per cent to 251.6bn yen, boosted in part by its acquisition of OSI Pharmaceuticals in June 2010.

In Europe sales increased by 5 per cent in the quarter to 54.9bn yen, while Japanese sales rose by 139.3bn yen. Sales in the Americas increased by 21 per cent to 48.2bn for the quarter, while sales in Asia rose by 1.6 per cent to 9bn yen.

The company reported that second quarter R&D expenses had risen by 13 per cent to 43.5bn yen, while selling, general and administrative expenses increased by 11.5 per cent to 125.3bn yen for the quarter.

1st August 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

Australian Flu and the dilemma of naming diseases
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....